Paper Details

  1. Home
  2. Paper Details

Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension.

Author: BarrAlasdair M, BoydaHeidi N, FredriksonDiane H, HonerWilliam G, ProcyshynRic M, TseLurdes

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Second-generation antipsychotics (SGAs) are associated with significant metabolic side effects, including dyslipidemia and hypertension. This review evaluated the effects of adjunct medications on lipid levels and blood pressure in patients taking SGAs. The review found that statins, conventional lipid-lowering agents, fluvoxamine, ramelteon, topiramate, valsartan, telmisartan, omega-3 fatty acids, metformin, and a combination of metformin-sibutramine seemed to have beneficial effects on lipid levels. Valsartan, telmisartan, and topiramate appeared to be effective for controlling increases in blood pressure.
Paper Details　
Original Abstract of the Article :
Second-generation antipsychotics (SGAs) are associated with significant comorbid metabolic abnormalities. Adjunct medications may be prescribed to treat these metabolic side effects, but the evidence supporting this practice (especially for the management of antipsychotic-associated dyslipidemia and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/YIC.0000000000000014

データ提供：米国国立医学図書館（NLM）

Managing Metabolic Side Effects of Antipsychotic Medications: A Challenging Terrain

This review explores the pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. The authors analyze a collection of studies, evaluating the effectiveness of different adjunct medications in managing these metabolic side effects. The review highlights the challenges associated with treating these metabolic abnormalities, emphasizing the need for evidence-based approaches to ensure optimal patient outcomes.

Navigating Metabolic Side Effects: A Quest for Effective Treatments

This review highlights the need for effective and well-tolerated treatments for managing antipsychotic-induced dyslipidemia and hypertension. The authors provide a comprehensive overview of the current evidence on the effectiveness of various adjunct medications, recognizing the importance of personalized approaches to optimize patient outcomes. The review is a journey through the complex landscape of antipsychotic-induced metabolic side effects, seeking to identify effective solutions for patients.

Balancing the Scales: Managing Metabolic Side Effects in Antipsychotic Treatment

The review underscores the importance of balancing the benefits of antipsychotic medication with the potential for metabolic side effects. The authors encourage healthcare professionals to proactively monitor patients for metabolic changes and to consider implementing adjunct medications when necessary to mitigate these risks. This approach to antipsychotic treatment, like a skillful camel guide navigating a challenging desert terrain, emphasizes the need for a delicate balance between therapeutic benefits and potential risks.

Dr.Camel's Conclusion

This review, like a well-worn trail through a vast desert, sheds light on the complex challenges of managing metabolic side effects associated with antipsychotic medication. The authors provide valuable insights into the effectiveness of various adjunct medications, urging healthcare professionals to adopt evidence-based approaches to ensure optimal patient outcomes. The review encourages continued research and innovation in this area, seeking to improve the lives of patients by mitigating the risks and enhancing the benefits of antipsychotic treatment.
Date :
  1. Date Completed 2014-12-03
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

24169026

DOI: Digital Object Identifier

10.1097/YIC.0000000000000014

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.